| [1] |
Desantis C, Ma J, Bryan L, et al. Breast cancer statistics,2013[EB/OL]. [2014-02-10]. http: / /www. cancer. org/research/cancerfactsstatistics/breast-cancer-facts-figures.
|
| [2] |
Partridge AH, Pagani O, Abulkhair O, et al. First international consensus guidelines for breast cancer in young women (BCY1)[J]. Breast,2014,23(3): 209-220.
|
| [3] |
Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years[J]. Semin Oncol,2009,36(3): 237-249.
|
| [4] |
Assi HA, Khoury KE, Dbouk H, et al. Epidemiology and prognosis of breast cancer in young women[J]. J Thorac Dis,2013,5(Suppl 1): S2-8.
|
| [5] |
Collaborative Group on Hormonal Factors in Breast Cancer.Menarche, menopause, and breast cancer risk: individual participant meta-analysis,including 118 964 women with breast cancer from 117 epidemiological studies [J]. Lancet Oncol,2012,13(11): 1141-1151.
|
| [6] |
Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer[J]. Nat Genet, 2000,26 (4): 411-414.
|
| [7] |
Lalloo F, Evans DG. Familial breast cancer [J]. Clin Genet,2012,82(2): 105-114.
|
| [8] |
Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models[J]. Future Oncol,2010,6(3): 355-365.
|
| [9] |
Fischer C, Kuchenbäcker K, Engel C, et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium[J]. J Med Genet,2013,50(6): 360-367.
|
| [10] |
National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian,v.4.2013[EB/OL].[2013-12-20]. http: / /www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
|
| [11] |
Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer[J]. J Natl Cancer Inst,1999,91(14): 1241-1247.
|
| [12] |
Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors [J]. J Genet Couns,2012,21(2): 151-161.
|
| [13] |
Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography,breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer [J]. J Am Coll Radiol,2010,7(1): 18-27.
|
| [14] |
American College of Radiology. ACR practice guidelines for the performance of screening and diagnostic mammography, revised 2013[EB/OL]. [2013-08-09]. http: / /www.acr.org / ～/media/ACR/Documents/PGTS/guidelines/Screening _ Mammography.pdf.
|
| [15] |
Weigert J,Steenbergen S. The connecticut experiment: the role of ultrasound in the screening of women with dense breasts[J].Breast J,2012,18(6): 517-522.
|
| [16] |
沈松杰,孙强,徐雅莉,等. 乳腺癌常用早期诊断方法的比较研究[J].中华肿瘤杂志,2012,34(11),877-880.
|
| [17] |
American College of Radiology. ACR practice guideline for performing and interpreting magnetic resonance imaging(MRI), revised 2013[EB/OL]. [2013-08-09]. http: / /www. acr. org/ ～ /media/ACR/Documents/PGTS/guidelines/MRI.pdf.
|
| [18] |
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer screening and diagnosis.v.2.2013[EB/OL]. [2013-12-20]. http: / /www. nccn. org/professionals/physician_gls/pdf/breast-screening.pdf.
|
| [19] |
Steward WP, Brown K. Cancer chemoprevention: a rapidly evolving field [J]. Br J Cancer,2013,109(1): 1-7.
|
| [20] |
Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer[J]. Breast Cancer,2014,6: 29-36.
|
| [21] |
Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women[J]. N Engl J Med,2011,364(25): 2381-2391.
|
| [22] |
Cuzick J,Sestak I,Forbes JF,et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-Ⅱ): an international, double-blind, randomised placebocontrolled trial[J]. Lancet,2014,383(9922): 1041-1048.
|
| [23] |
Fagerlin A,Dillard AJ,Smith DM,et al. Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid[J]. Breast Cancer Res Treat,2011,127(3): 681-688.
|
| [24] |
McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005[J]. Cancer,2009,115(23): 5404-5412.
|
| [25] |
Soran A,Kamali Polat A,Johnson R,et al. Increasing trend of contralateral prophylactic mastectomy: What are the factors behind this phenomenon?[J]. Surgeon,2014,doi: 10.1016/j.surge.2014.02.005.
|
| [26] |
Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis [ J]. Ann Oncol, 2013, 24 (8 ): 2029-2035.
|
| [27] |
Pilgrim S, Pain S. Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers[J]. Eur J Surg Oncol,2014,40(6): 670-672.
|
| [28] |
Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction[J]. J Natl Compr Canc Netw, 2010, 8 (10): 1112-1146.
|